Skip to main content
Download PDF
  • Research article
  • Open access
  • Published:

Substantial health and economic burden of COVID-19 during the year after acute illness among US adults at high risk of severe COVID-19

BMC Medicine volume 22, Article number: 46 (2024) Cite this article

Abstract

Background

Post-COVID conditions encompass a range of long-term symptoms after SARS-CoV-2 infection. The potential clinical and economic burden in the United States is unclear. We evaluated diagnoses, medications, healthcare use, and medical costs before and after acute COVID-19 illness in US patients at high risk of severe COVID-19.

Methods

Eligible adults were diagnosed with COVID-19 from April 1 to May 31, 2020, had ≥ 1 condition placing them at risk of severe COVID-19, and were enrolled in Optum’s de-identified Clinformatics® Data Mart Database for ≥ 12 months before and ≥ 13 months after COVID-19 diagnosis. Percentages of diagnoses, medications, resource use, and costs were calculated during baseline (12 months preceding diagnosis) and the post-acute phase (12 months after the 30-day acute phase of COVID-19). Data were stratified by age and COVID-19 severity.

Results

The cohort included 19,558 patients (aged 18–64 y, n = 9381; aged ≥ 65 y, n = 10,177). Compared with baseline, patients during the post-acute phase had increased percentages of blood disorders (16.3%), nervous system disorders (11.1%), and mental and behavioral disorders (7.7%), along with increases in related prescriptions. Overall, there were substantial increases in inpatient and outpatient healthcare utilization, along with a 23.0% increase in medical costs. Changes were greatest among older patients and those admitted to the intensive care unit for acute COVID-19 but were also observed in younger patients and those who did not require COVID-19 hospitalization.

Conclusions

There is a significant clinical and economic burden of post-COVID conditions among US individuals at high risk for severe COVID-19.

Peer Review reports

Background

Post-COVID conditions are characterized by symptoms of COVID-19 that extend beyond the initial recovery from acute illness [1,2,3]. Presentation is highly variable across patients and may include residual symptoms that persist after acute illness, persistent organ dysfunction, or new symptoms or syndromes that develop after initial recovery from COVID-19 [1,2,3]. Post-COVID conditions often affect multiple organ systems, persist for several months, and have a substantial impact on daily functioning and productivity [4]. The clinical diagnosis, termed post-acute sequelae of COVID-19 (PASC), was officially defined and assigned an International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), code (U09.9) in October 2021 [5, 6], but a widely accepted case definition and associated symptom timeframe is still under development.

Multiple studies have identified post-COVID conditions as a frequent result of COVID-19 illness [1, 7,8,9,10], but prevalence estimates vary. The Centers for Disease Control and Prevention (CDC) recently reported that 38.2% of patients diagnosed with COVID-19 experienced ≥ 1 post-COVID condition from 30 to 365 days following diagnosis [10]. The World Health Organization reports a range from 10% to 20% of patients diagnosed with COVID-19 [2], and other studies have reported rates of up to 57% 6 months after diagnosis [8, 11,12,13,14]. Heterogeneous cohorts likely contribute to varying results given that certain characteristics, such as female sex and older age, are associated with developing long-term sequelae [15, 16].

Although the risk of post-COVID conditions has been associated with more severe cases of acute illness, it can occur across all levels of COVID-19 severity [1, 15, 17]. In a systematic review of > 2000 studies conducted worldwide among patients with varying disease severity, more than half of patients who recovered from acute illness experienced long-term sequelae for ≥ 6 months after diagnosis [8]. In 2 studies from Germany and the Faroe Islands of mainly nonhospitalized patients with asymptomatic or mild to moderate acute illness, approximately 28% to 53% of patients experienced persistent symptoms of COVID-19 months later [11, 13].

The potential for post-COVID conditions to develop in patients with mild or moderate illness is particularly relevant as new variants emerge, such as the highly transmissible Omicron variant, which is associated with milder illness compared with earlier strains [18,19,20,21]. In the context of these variants, immunity from natural infection or vaccination may provide better protection against severe disease than against overall infection [21]. Moreover, evidence suggests that risk of developing long-term symptoms may vary by circulating strain [22, 23]. The effects of these changes on population-level incidence of post-COVID conditions remain to be determined, but it is likely that the true burden of COVID-19 in terms of reduced quality of life, loss of productivity, strains on healthcare systems, and economic impact reaches far beyond acute infection.

Emerging data on long-term COVID-19 impact indicate a substantial healthcare burden. In 2 studies using the US Department of Veterans Affairs database, patients with COVID-19 compared with a control cohort had increased healthcare resource and medication use, as well as abnormalities across multiple organ systems, during the year after diagnosis [24, 25]. Other studies in patients with COVID-19 have identified increases in COVID-19─related healthcare provider visits, emergency department (ED) visits, and readmissions for up to 7 months after diagnosis [26,27,28]. However, comparison studies are often limited by the small numbers of patients and high variability between patient characteristics.

The aim of this retrospective analysis was to describe morbidity, healthcare resource use, and costs associated with the post-acute phase of COVID-19 among patients with underlying medical conditions or characteristics associated with higher risk of severe COVID-19 (hereafter referred to as “high risk”) in the United States [29]. This population was selected based on immediate relevance of the data to emerging COVID-19 treatments, which are authorized first for high-risk patients. To maintain focus on descriptive results and the guiding of hypothesis generation for future research, no formal comparisons were planned.

Methods

Study design and data source

This was a descriptive, retrospective, cohort study in patients diagnosed with COVID-19 between April 1 and May 31, 2020, in which each patient served as their own control for evaluation of diagnoses, medications, healthcare utilization, and costs before versus after acute COVID-19. Patients were identified using administrative health claims from Optum’s de-identified Clinformatics® Data Mart Database (CDM), which contains de-identified patient-level information derived from administrative healthcare claims from commercial and Medicare Advantage health plan members in all 50 states. Claims encompass medical and pharmacy healthcare services and include information regarding healthcare costs and resource utilization.

The index period was April 1 to May 31, 2020, and the index date was defined as the date of the first COVID-19 diagnosis. Individual patient data were described during the 12 months before the index date (baseline phase) and during the 12 months after the end of the 30-day acute phase [3] of COVID-19 illness (Fig. 1). For patients whose hospital stays spanned across study phases, total numbers of events and associated costs were calculated per hospitalization day and were attributed to each phase based on the number of days falling within that phase.

Fig. 1
figure 1

Study design. The date of first COVID-19 diagnosis was defined as the index date, and the index period was April 1 through May 31, 2020. For each patient, the baseline phase included the 12 months before the index date, and the post-acute phase included the 12 months after the end of the acute phase of COVID-19 illness. aThe acute phase, defined as the 30-day period after the index date, was excluded from analysis

Full size image

Participants

Patients were eligible for inclusion if they had ≥ 1 ICD-10 diagnosis code for confirmed COVID-19 (U07.1) during the index period. Patients were required to have continuous enrollment (gaps of ≤ 45 days were permitted) in Optum CDM over the 12 months before and 13 months after COVID-19 diagnosis, to be aged ≥ 18 years on the index date, and to have ≥ 1 high risk condition per CDC definition as of October 14, 2021 [29]. Sentinel code lists [30] were used to define these conditions when available, and all codes were reviewed by sponsor personnel with medical expertise (FD, JCA, NB, MLNFV). Criteria for immunocompromised individuals were developed from a recent literature review [31]. Inclusion criteria specified having a diagnosis code (ICD-10-CM), procedure code (ICD-10-Procedure Coding System [ICD-10-PCS], Current Procedural Terminology [CPT®], Healthcare Common Procedures Coding System [HCPCS]), or National Drug Code (NDC) for ≥ 1 of the listed conditions within the 12 months before the index date or being aged ≥ 65 years at the index date. Patients were excluded if they were hospitalized for ≥ 5 consecutive days during the baseline phase; spent any time at a long-term care facility, skilled nursing facility, inpatient rehabilitation, or hospice during baseline or at index date; had an ICD-10 code for confirmed COVID-19 before the index period; or died during the acute phase of COVID-19.

Descriptive analysis

Outcomes of interest included ICD-10 diagnosis codes (other than confirmed COVID-19); medication use; outpatient visits and laboratory tests; ED visits; inpatient hospitalizations, including length of stay (LOS), intensive care unit (ICU) visits/LOS, ventilator use, and 30-day readmissions; and both standard and nonzero healthcare-associated costs. Standard costs were calculated based on all patients with a related visit or service, and nonzero costs were calculated based on all patients with a cost > 0 associated with that visit or service. The top 500 individual diagnosis codes were aggregated to their chapter and broader diagnostic categories and used for further analysis. Medications were analyzed via AnalySource® (Fayetteville, NY, USA) according to the Uniform System of Classification class. Diagnoses and medications were calculated as dichotomous occurrences during the 12 months before the index date (baseline phase) and the 12 months after the 30-day acute phase (post-acute phase); those with a prevalence of < 2% within the overall population during the baseline phase were excluded. Biologics were also excluded because the category primarily consisted of incompletely captured vaccine data. No adjustments were made for patients who died during the 12-month post-acute phase; all deaths that occurred during the post-acute phase were accounted for and reported. Continuous measures were totaled for each period. For each outcome, absolute and relative change from baseline to the post-acute phase was calculated using frequency counts.

Because older age is a risk factor for both increased COVID-19 severity and post-COVID conditions [21], data were separated into categories of patients aged 18 to 64 years or aged ≥ 65 years at the index date. To better understand the relationship between post-COVID conditions and acute COVID-19 severity, data were also stratified according to patient disposition during acute COVID-19 illness: not hospitalized, hospitalized without ICU admission, or admitted to the ICU. All variables were presented descriptively using mean ± SD or median (quartile 1 [Q1]; quartile 3 [Q3]) for continuous variables and frequencies and percentages for categorical variables. No statistical inference tests were conducted. Analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA).

Results

Patient population

The full cohort included 19,558 patients with a median (Q1; Q3) age of 66 (51; 74) years (Table 1). A slight majority of patients were female (55.4%), White (52.3%), enrolled in Medicare (54.7%), and aged ≥ 65 years (52.0%). When categorized by acute COVID-19 severity, 15,457 patients (79.0%) did not require hospitalization, 2916 patients (14.9%) were hospitalized without ICU admission, and 1185 patients (6.1%) were admitted to the ICU. Male patients, Black patients, and those aged ≥ 65 years were observed in higher proportions among the cohorts that were hospitalized (with or without ICU admission) for COVID-19.

Table 1 Baseline demographic characteristics
Full size table

The majority of patients (81.5%) had ≥ 2 high-risk conditions, and 7.7% of patients had ≥ 8 such conditions (Table 2). The most common high-risk conditions in the overall population were immunocompromised state (71.2%), hypertension (60.5%), and age ≥ 65 years (52.0%). Most conditions were more common among older patients and among those who were hospitalized (with or without ICU admission) for acute COVID-19.

Table 2 Baseline medical characteristics, including presence of high-risk conditionsa
Full size table

Most patients (82.7%) were diagnosed with COVID-19 in the outpatient setting (Table 2). Of those who were hospitalized at any time during the acute phase, 143 patients (0.7%) had hospital stays spanning > 30 days after the index date and therefore overlapping the acute and post-acute phases. Few patients (0.5% of the overall cohort) died during the post-acute phase. A full list of reasons for exclusion from the analysis is shown in Table S1.

Diagnoses

Between the baseline and post-acute phases, the frequency of individual ICD-10-CM diagnosis codes increased within several chapters (Fig. 2). The greatest percentage increase was observed in the ICD-10 chapter of “diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism” (+ 16.3%), followed by “diseases of the nervous system” (+ 11.1%), “external causes of morbidity and mortality” (+ 7.9%), and “mental and behavioral disorders” (+ 7.7%).

Fig. 2
figure 2

Percentage change from baseline to post-acute phase in ICD-10 diagnoses in the overall population (N = 19,558). Diagnosis codes (shown in parentheses) include those with a prevalence of ≥ 2% in the baseline population and with an increase from baseline to post-acute phases. Code ranges, raw values at baseline and post-acute phases, and diagnoses decreasing from baseline to post-acute phases are shown in Table 3. ICD-10, International Classification of Diseases, Tenth Revision

Full size image

Frequencies of other disorders increased more modestly or decreased (Table 3); the greatest percentage decrease was observed in the chapter of “diseases of the respiratory system” (–18.3%). Within this chapter, the decrease was driven specifically by a drop in frequency of the subchapters acute upper and lower respiratory infections (–56.6% and –69.3%, respectively), which outweighed increases in frequency of other respiratory conditions, such as “other respiratory diseases principally affecting the interstitium” (+ 59.8%; Table S2 and Fig. S1).

Table 3 Diagnoses during the baseline and post-acute phases in the overall population (N = 19,558)a
Full size table

Medication use

Prescription frequencies across several medication classes increased between baseline and the post-acute phase (Fig. 3). The greatest percentage increases were observed for vitamins (+ 47.5%), miscellaneous preparations (+ 38.0%), blood factors (+ 31.6%), and hemostatic modifiers (+ 29.9%). Among medication classes with increases of ≥ 10% in the overall population, increases in prescription frequency were observed across all ages and severities (Tables 4 and 5).

Fig. 3
figure 3

Percentage change from baseline to post-acute phase in prescription frequency in the overall population (N = 19,558). Medication classes shown are according to USC designations; included classes are those prescribed to ≥ 2% of the baseline population and with a percentage change from baseline to post-acute phase of ≥ 10%. Percentage changes from baseline to post-acute phase according to age group and disease severity are shown in Table 4, and raw values during baseline and post-acute phases for all medication classes regardless of percentage change are shown for the overall population in Table S3. USC, Uniform System of Classification

Full size image
Table 4 Medications with frequency Increases ≥ 10% from the baseline to the post-acute phasea by age group
Full size table
Table 5 Medications with frequency increases ≥ 10% from baseline to post-acute phasea by disposition during acute COVID-19
Full size table

Other prescription frequencies increased marginally or decreased (Table S3). The greatest overall decreases were within the classes of cough/cold/flu preparations (− 73.7%), antimalarials (–54.5%), and antivirals (–40.4%).

Medical care and hospitalizations

Increases in total and per-patient inpatient and outpatient visits and procedures were observed during the post-acute phase compared with baseline (Tables 6 and 7). The greatest percentage increases were observed for LOS (including total days [+ 165.6%] and mean days per patient [+ 132.9%]), inpatient lab tests (+ 105.1%), and all-cause readmissions within 30 days (+ 249.9%). For these 3 variables, increases from baseline to the post-acute phase were greatest among patients who were admitted to the ICU during acute COVID-19, but were substantial even among those who did not require hospitalization for acute COVID-19. The number of patients with ICU visits was relatively consistent from baseline to the post-acute phase in the overall population but increased by 43.2% among those who were admitted to the ICU during acute COVID-19 illness. Among all age and severity categories, the numbers of patients visiting the ED decreased. Regarding hospital discharge status, percentages of all discharges to another hospital department or facility (such as hospice care or a skilled nursing facility) were low during the baseline phase owing to exclusion criteria but substantially increased among both age groups (up to a 13,000% increase in intra-institution transfers among patients aged ≥ 65 years; Table S4).

Table 6 Healthcare resource use during baseline and post-acute phasesa in the overall population and by age
Full size table
Table 7 Healthcare resource use during baseline and post-acute phasesa stratified by disposition during acute COVID-19
Full size table

Healthcare costs

In the overall population, total medical costs (including prescription, inpatient, and outpatient costs) increased by 23.0% from the baseline to the post-acute phase (Table 8). Increased percentages were observed across all categories of age and acute COVID-19 severity but were greater among patients aged ≥ 65 years (+ 27.2%) versus younger patients (+ 16.7%) and were greater among patients admitted to the ICU during the acute phase of COVID-19 (+ 70.6%) versus those who were not hospitalized (+ 14.3%) or who were hospitalized without ICU admission (+ 27.9%; Tables 8 and 9).

Table 8 Medical costs during baseline and post-acute phasesa in the overall population and by ageb
Full size table
Table 9 Medical costs during baseline and post-acute phasesa stratified by disposition during acute COVID-19b
Full size table

Inpatient and outpatient costs also increased in the overall population and across all age and severity categories (Tables 8 and 9). Percentage increases in inpatient costs were driven primarily by cost increases among patients of any age who were admitted to the ICU during acute COVID-19 (+ 267.4%). Much of the increase in inpatient costs within this patient subpopulation was due to an 896% increase in 30-day all-cause readmissions (Table 7), resulting in a 1227.7% cost escalation during the post-acute phase. Outpatient costs increased more modestly and were greatest among older patients and those who were hospitalized (with or without ICU admission) during acute COVID-19. Overall outpatient cost increases were observed despite decreases associated with ED visits across all age and severity categories.

Discussion

In this retrospective analysis encompassing > 2 years of healthcare data from nearly 20,000 high-risk individuals diagnosed with COVID-19, resource use and costs were substantially higher in the year after acute COVID-19 illness compared with the previous year. Consistent with previous observations [15], increases were greatest among older individuals and those who required hospitalization for acute COVID-19; however, notable changes were observed even among younger patients and those who had less severe acute disease.

We found increases in incidence of blood-related, neurologic, and psychiatric disorders, all of which are consistent with previous reports on post-COVID conditions [32,33,34]. We observed a 16.3% increase in the ICD-10 diagnostic codes comprising “diseases of the blood and blood-forming organs” along with 31.6% and 29.9% increases in blood factor prescriptions and hemostatic modifier prescriptions, respectively. This is consistent with the potential for COVID-19 to cause persistent changes in the mechanisms underlying coagulation and hemostasis [33]. An 11.1% increase in “diseases of the nervous system” and a 7.7% increase in “mental and behavioral disorders” were also observed alongside increased prescribing of neurologic/neuromuscular disorder treatments and psychotherapeutic drugs (+ 12.7% and + 11.1%, respectively). The magnitude of increases in mental health–related prescriptions were relatively similar among patients who were not hospitalized during acute COVID-19 illness compared with the overall cohort, supporting previous reports that identified long-term impairments in mood, anxiety, and cognitive functioning that were unrelated to COVID-19 severity or hospitalization [32, 34, 35]. Our results are further corroborated by a longitudinal study of UK Biobank participants, in which cognitive declines observed > 3 months after COVID-19 diagnosis were significant even among nonhospitalized cases and were associated with structural changes in the brain [35]. In contrast with recent CDC data [10], we did not observe an overall increase in respiratory conditions because acute respiratory infections decreased. CDC defined respiratory conditions only as acute pulmonary embolism, asthma, or respiratory symptoms.

The percentages of outpatient and inpatient medical service use were substantially higher during the post-acute phase compared with baseline, including a 165.6% increase in total days spent in the hospital and a 249.9% increase in 30-day all-cause readmissions. This increase in healthcare utilization was directly reflected in observed medical costs. Total costs increased by 23.0% in the overall population; increases were greater among patients aged ≥ 65 years compared with the younger population and ranged from 14.3% among patients who were not hospitalized for acute COVID-19 to 70.6% among those admitted to the ICU.

Mean overall per-patient medical cost during the year after the acute COVID-19 phase was approximately $27,000 (whereas the baseline cost was approximately $22,000). Although there are no direct comparisons that can be made with previous studies, cost estimates of post-COVID conditions based on similar diagnoses (eg, myalgic encephalomyelitis/chronic fatigue syndrome) were nearly $9000 per person per year [36]. The higher values observed in our study may reflect a greater impact of COVID-19 than similar conditions but could also be a result of our high-risk patient population. Notably, studies comparing post-COVID conditions with long-term sequelae after seasonal influenza found a greater symptom, diagnosis, and healthcare resource burden with COVID [12, 24].

Substantial decreases were observed in the percentages of acute upper and lower respiratory infections, prescriptions for cough/cold/flu preparations, and ED visits. These data are consistent with early reports in the United States that show a sharp decline in both influenza rates and ED visits after the onset of the pandemic, including ED visits specifically for non-COVID upper respiratory infections [37,38,39]. This decline was likely due to a combination of reduced influenza circulation because of COVID-19 mitigation strategies and the reluctance of patients to seek treatment because of the perceived risk of contracting COVID-19 in a healthcare setting [37, 39].

A main strength of this study was that all patients served as their own control, which inherently adjusts for potential confounders, including patient demographics and stable characteristics, such as healthcare-seeking behavior. Our study had some limitations, including that the population was limited to commercially insured individuals who were diagnosed early in the pandemic and who survived the acute phase of COVID-19. There was also potential for incomplete data capture (due to nonbillable diagnoses) and surveillance bias by which those who contracted COVID-19 were under higher medical scrutiny following their diagnosis. It is important to note that the study was conducted during a time of low preexisting immunity (ie, before vaccination and previous infection) and before the emergence of and SARS-CoV-2 variants of concern. Such factors could limit the generalizability of the findings to the current landscape. Additionally, baseline assessments were performed during the pre-pandemic period, whereas post-acute COVID-19 assessments were performed during a public health emergency that altered healthcare practices, access, and considerations; these changes may have affected clinical burden and healthcare costs during the post-acute COVID-19 period. Because this study included only high-risk individuals, a companion report describes results from a separate cohort of patients without high risk of developing severe COVID-19.

Conclusion

The health and economic burden of post-COVID conditions among high-risk US adults is substantial. Although the greatest impacts were observed among patients aged ≥ 65 years and those who were admitted to the ICU for acute COVID-19, increases in most outcomes were apparent even among younger individuals and those who did not require COVID-19 hospitalization. These results improve our understanding of post-COVID conditions and associated costs, as well as support hypothesis generation for future work characterizing the COVID-19 impact on individuals and society.

Availability of data and materials

Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions, and exceptions, Pfizer may also provide access to the related individual de-identified participant data. See https://www.pfizer.com/science/clinical-trials/trial-data-and-results for more information.

Abbreviations

CDC:

US Centers for Disease Control and Prevention

CDM:

Optum’s de-identified Clinformatics® Data Mart Database

CPT:

Current Procedural Terminology

ED:

Emergency department

HCPCS:

Healthcare Common Procedure Coding System

ICD-10:

International Classification of Diseases, 10th Revision

ICD-10-CM:

International Classification of Diseases, 10th Revision, Clinical Modification

ICD-10-PCS:

International Classification of Diseases, 10th Revision, Procedure Coding System

ICU:

Intensive care unit

LOS:

Length of stay

LTCF:

Long-term care facility

NC:

Not calculable

NDC:

National Drug Code

PASC:

Post-acute sequelae of COVID-19

Q1:

Quartile 1

Q3:

Quartile 3

SAS:

Statistical analysis software

SNF:

Skilled nursing facility

USC:

Uniform System of Classification

USD:

United States dollars

References

  1. Amenta EM, Spallone A, Rodriguez-Barradas MC, El Sahly HM, Atmar RL, Kulkarni PA. Postacute COVID-19: an overview and approach to classification. Open Forum Infect Dis. 2020;7(12):ofaa509.

    Article  PubMed  PubMed Central  Google Scholar 

  2. World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus. World Health Organization. Available at: https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1. Accessed 8 June 2022.

  3. Centers for Disease Control and Prevention. Post-COVID conditions: information for healthcare providers. Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html. Accessed 23 June 2022.

  4. Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re’em Y, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Centers for Disease Control and Prevention. New ICD-10-CM code for post-COVID conditions, following the 2019 Novel Coronavirus (COVID-19). Centers for Disease Control and Prevention. Available at: https://www.cdc.gov/nchs/data/icd/Announcement-New-ICD-code-for-Post-COVID-Condition-April-2022-final.pdf. Accessed 8 June 2022.

  6. McGrath LJ, Scott AM, Surinach A, Chambers R, Benigno M, Malhotra D. Use of the post-acute sequelae of COVID-19 diagnosis code in routine clinical practice in the US. JAMA Netw Open. 2022;5(5):e2235089.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Townsend L, Dowds J, O’Brien K, Sheill G, Dyer AH, O’Kelly B, et al. Persistent poor health after COVID-19 is not associated with respiratory complications or initial disease severity. Ann Am Thorac Soc. 2021;18(6):997–1003.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Groff D, Sun A, Ssentongo AE, Ba DM, Parsons N, Poudel GR, et al. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw Open. 2021;4(10):e2128568.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Petersen EL, Gossling A, Adam G, Aepfelbacher M, Behrendt CA, Cavus E, et al. Multi-organ assessment in mainly non-hospitalized individuals after SARS-CoV-2 infection: The Hamburg City Health Study COVID programme. Eur Heart J. 2022;43(11):1124–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Bull-Otterson L, Baca S, Saydah S, Boehmer TK, Adjei S, Gray S, et al. Post-COVID conditions among adult COVID-19 survivors aged 18–64 and ≥65 years — United States, March 2020–November 2021. MMWR Morb Mortal Wkly Rep. 2022;71(21):713–7.

    Article  CAS  PubMed Central  Google Scholar 

  11. Petersen MS, Kristiansen MF, Hanusson KD, Danielsen ME, Steig B, Gaini S, et al. Long COVID in the Faroe Islands: a longitudinal study among nonhospitalized patients. Clin Infect Dis. 2021;73(11):e4058–63.

    Article  CAS  PubMed  Google Scholar 

  12. Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M, Harrison PJ. Incidence, co-occurrence, and evolution of long-COVID features: a 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. 2021;18(9):e1003773.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Augustin M, Schommers P, Stecher M, Dewald F, Gieselmann L, Gruell H, et al. Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. Lancet Reg Health Eur. 2021;6:100122.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep. 2021;11(1):16144.

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  15. Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID. Nat Med. 2021;27(4):626–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Bai F, Tomasoni D, Falcinella C, Barbanotti D, Castoldi R, Mule G, et al. Female gender is associated with long COVID syndrome: a prospective cohort study. Clin Microbiol Infect. 2022;28(4):611.e619–611.e616.

    Article  Google Scholar 

  17. Yoo SM, Liu TC, Motwani Y, Sim MS, Viswanathan N, Samras N, et al. Factors associated with post-acute sequelae of SARS-CoV-2 (PASC) after diagnosis of symptomatic COVID-19 in the inpatient and outpatient setting in a diverse cohort. J Gen Intern Med. 2022;37(8):1988–95.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Zhao H, Lu L, Peng Z, Chen LL, Meng X, Zhang C, et al. SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells. Emerg Microbes Infect. 2022;11(1):277–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Abdullah F, Myers J, Basu D, Tintinger G, Ueckermann V, Mathebula M, et al. Decreased severity of disease during the first global Omicron variant COVID-19 outbreak in a large hospital in Tshwane, South Africa. Int J Infect Dis. 2022;116:38–42.

    Article  CAS  PubMed  Google Scholar 

  20. Meo SA, Meo AS, Al-Jassir FF, Klonoff DC. Omicron SARS-CoV-2 new variant: global prevalence and biological and clinical characteristics. Eur Rev Med Pharmacol Sci. 2021;25(24):8012–8.

    CAS  PubMed  Google Scholar 

  21. Chenchula S, Karunakaran P, Sharma S, Chavan M. Current evidence on efficacy of COVID-19 booster dose vaccination against the Omicron variant: a systematic review. J Med Virol. 2022;94(7):2969–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Spinicci M. SARS-CoV-2 variants may induce different long COVID phenotypes. Presented at: European Congress of Clinical Microbiology & Infectious Diseases. Lisbon. 2022.

  23. Antonelli M, Pujol JC, Spector TD, Ourselin S, Steves CJ. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet. 2022;399(10343):2263–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594(7862):259–64.

    Article  ADS  CAS  PubMed  Google Scholar 

  25. Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022;28(3):583–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Menges D, Ballouz T, Anagnostopoulos A, Aschmann HE, Domenghino A, Fehr JS, et al. Burden of post-COVID-19 syndrome and implications for healthcare service planning: a population-based cohort study. PLoS ONE. 2021;16(7): e0254523.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Romero-Duarte A, Rivera-Izquierdo M, Guerrero-Fernandez de Alba I, Perez-Contreras M, Fernandez-Martinez NF, Ruiz-Montero R, et al. Sequelae, persistent symptomatology and outcomes after COVID-19 hospitalization: the ANCOHVID multicentre 6-month follow-up study. BMC Med. 2021;19(1):129.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Lavery AM, Preston LE, Ko JY, Chevinsky JR, DeSisto CL, Pennington AF, et al. Characteristics of hospitalized COVID-19 patients discharged and experiencing same-hospital readmission - United States, March-August 2020. MMWR Morb Mortal Wkly Rep. 2020;69(45):1695–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Centers for Disease Control and Prevention. Underlying medical conditions associated with higher risk for severe COVID-19: information for healthcare professionals. Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html. Accessed 9 Jan 2022.

  30. Yih WK, Hua W, Draper C, Dutcher S, Fuller C, Kempner M, et al. Sentinel COVID-19 natural history master protocol. US Food and Drug Administration. Available at: https://www.sentinelinitiative.org/sites/default/files/Methods/COVID-19-Natural_History_Protocol_v3.0.pdf. Accessed 8 June 2022.

  31. Di Fusco M, Lin J, Vaghela S, Lingohr-Smith M, Nguyen JL, Scassellati Sforzolini T, et al. COVID-19 vaccine effectiveness among immunocompromised populations: a targeted literature review of real-world studies. Expert Rev Vaccines. 2022;21(4):435–51.

    Article  PubMed  Google Scholar 

  32. Lamontagne SJ, Winters MF, Pizzagalli DA, Olmstead MC. Post-acute sequelae of COVID-19: evidence of mood & cognitive impairment. Brain Behav Immun Health. 2021;17:100347.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Pretorius E, Vlok M, Venter C, Bezuidenhout JA, Laubscher GJ, Steenkamp J, et al. Persistent clotting protein pathology in long COVID/post-acute sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc Diabetol. 2021;20(1):172.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Houben-Wilke S, Goertz YM, Delbressine JM, Vaes AW, Meys R, Machado FV, et al. The impact of long COVID-19 on mental health: observational 6-month follow-up study. JMIR Ment Health. 2022;9(2): e33704.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Douaud G, Lee S, Alfaro-Almagro F, Arthofer C, Wang C, McCarthy P, et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature. 2022;604(7907):697–707.

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  36. Cutler DM. The costs of long COVID. JAMA Health Forum. 2022;3(5):e221809.

    Article  PubMed  Google Scholar 

  37. Giannouchos TV, Biskupiak J, Moss MJ, Brixner D, Andreyeva E, Ukert B. Trends in outpatient emergency department visits during the COVID-19 pandemic at a large, urban, academic hospital system. Am J Emerg Med. 2021;40:20–6.

    Article  PubMed  Google Scholar 

  38. Hartnett KP, Kite-Powell A, DeVies J, Coletta MA, Boehmer TK, Adjemian J, et al. Impact of the COVID-19 pandemic on emergency department visits - United States, January 1, 2019-May 30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(23):699–704.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Olsen SJ, Azziz-Baumgartner E, Budd AP, Brammer L, Sullivan S, Pineda RF, et al. Decreased influenza activity during the COVID-19 pandemic - United States, Australia, Chile, and South Africa, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(37):1305–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors thank Nathalie Baillon-Plot and Maria Lavinea Novis de Figueiredo Valente of Pfizer Inc for their help with study design and manuscript preparation. Programming support and expertise were provided by Tomasz Mikolajczyk, Klaudia Niezabitowska, and Kirsten Astbury, all of Quanticate, and Maya Reimbaeva of Pfizer Inc. Editorial/medical writing support was provided by Anna Stern, PhD, of ICON (Blue Bell, PA, USA) and was funded by Pfizer Inc.

Funding

This work was supported by Pfizer Inc.

Author information

Authors and Affiliations

  1. Global Real World Evidence, Pfizer Inc, New York, NY, USA

    Amie Scott, Michael Benigno, Leah McGrath & Deepa Malhotra

  2. Global HEOR, Pfizer Inc, New York, NY, USA

    Wajeeha Ansari & Manuela Di Fusco

  3. Vaccines Medical Development & Scientific Clinical Affairs, Pfizer Inc, New York, NY, USA

    Farid Khan, Jennifer Nguyen & Jessica E. Atwell

  4. Global Product Development Statistics, Pfizer Inc, New York, NY, USA

    Richard Chambers

  5. Medical Affairs, Pfizer Inc, New York, NY, USA

    Florin Draica

  6. Medical Affairs, Pfizer Ltd, Tadworth, Surrey, UK

    Joanna Atkinson

Authors
  1. Amie Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wajeeha Ansari
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Farid Khan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Richard Chambers
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michael Benigno
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Manuela Di Fusco
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Leah McGrath
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Deepa Malhotra
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Florin Draica
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jennifer Nguyen
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Joanna Atkinson
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Jessica E. Atwell
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

AS, WA, FK, RC, MB, MDF, LM, FD, JN, JA1, and JA2 contributed to study concept and design; AS, RC, and MB analyzed the patient data; DM and all other authors interpreted the data and read and approved the final manuscript.

Corresponding author

Correspondence to Amie Scott.

Ethics declarations

Ethics approval and consent to participate

This study was considered exempt from review and the need for informed consent by Sterling Institutional Review Board because of the use of deidentified data.

Consent for publication

Not applicable.

Competing interests

All authors are employees of Pfizer Inc and may hold stock or stock options.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: Table S1.

Reasons for exclusion from the study.

Additional file 2: Table S2.

Diagnoses of the respiratory system during the baseline and post-acute phases in the overall population (N=19,558)a.

Additional file 3: Figure S1.

Percentage change from the baseline phase to the post-acute phase in frequency of ICD-10-CM “diseases of the respiratory system” in the overall population (N=19,558). Diagnosis codes shown include those applicable to ≥2% of the baseline population.

Additional file 4: Table S3.

Medication prescriptions during the baseline and post-acute phases in the overall population (N=19,558)a.

Additional file 5: Table S4.

Hospital discharge status during baseline and post-acute phasesa in the overall population and stratified by age.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Scott, A., Ansari, W., Khan, F. et al. Substantial health and economic burden of COVID-19 during the year after acute illness among US adults at high risk of severe COVID-19. BMC Med 22, 46 (2024). https://doi.org/10.1186/s12916-023-03234-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12916-023-03234-6

Keywords

BMC Medicine

ISSN: 1741-7015

Contact us